Lundbeck has gained ODD from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which ...

(Bloomberg) -- H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug ...

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Lundbeck has received the US Food and Drug Administration’s (FDA) fast track designation for its investigational drug amlenetug, a potential treatment for multiple system atrophy (MSA).

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its ...

Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. | Otsuka ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Accepting New Clients. Therapy is a journey that allows a person to become the best version of themselves through building on strengths and challenging beliefs that do not serve them. As a ...